CurveBeam AIASX:CVB -20.00% EBIT per Share is A$-0.04 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 691 Medical Devices & Instruments companies, CurveBeam AI ranks worse than 78% on this metric.
CurveBeam AI's EBIT per Share for the
six
months ended in Dec. 2025 was A$-0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.04.
During the past 3 years, the average EBIT per Share Growth Rate was -12.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for CurveBeam AI's EBIT per Share or its related term are showing as below:
ASX:CVB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -52.1 Med: -32.2 Max: -12.3
Current: -12.3
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of CurveBeam AI was -12.30% per year. The lowest was -52.10% per year. And the median was -32.20% per year.
ASX:CVB's 3-Year EBIT Growth Rate is ranked worse than 78% of 691
companies
in the Medical Devices & Instruments industry
Industry Median: 9.6
vs ASX:CVB: -12.30
CurveBeam AI's EBIT for the
six
months ended in Dec. 2025 was A$-9.41 Mil.
CurveBeam AI (ASX:CVB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
CurveBeam AI EBIT per Share Related Terms
CurveBeam AI EBIT per Share Historical Data
* Premium members only.
The historical data trend for CurveBeam AI's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CurveBeam AI (ASX:CVB) has a EBIT per Share of A$-0.04 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CurveBeam AI and its competitors. According to the industry distribution chart, CurveBeam AI ranks #539 out of 691 companies in the Medical Devices & Instruments industry, placing it in the top 78%.
Is CurveBeam AI's EBIT per Share too high?
CurveBeam AI's current EBIT per Share is A$-0.04. Based on the distribution chart, CurveBeam AI ranks #539 out of 691 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does CurveBeam AI's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #539 out of 691 companies for EBIT per Share. This places CurveBeam AI in the lower half of its industry. The industry median EBIT per Share is 9.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.60, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on CurveBeam AI and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current EBIT per Share is A$-0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current EBIT per Share of A$-0.04. The current EBIT per Share is A$-0.04. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current EBIT per Share is A$-0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CVB has been successfully added to your 